Vaxart Investor Relations Material

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s technology is designed to provide a safe, effective and affordable approach to vaccinate against infectious diseases, including H5N1 avian flu, dengue fever and other viruses that infect humans. It develops vaccines for chicken and swine flu strains that can be delivered via drinking water, or seasoned with salt or other flavorings to achieve mucosal immunity. The company is headquartered in South San Francisco, California.